- Home
- SECZ vs RIGL Comparison
SECZ vs RIGL Comparison
Compare SECZ & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SECZ | RIGL |
|---|---|---|
| Founded | 2017 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 884.9M |
| IPO Year | 2026 | 2000 |
Fundamental Metrics
Financial Performance| Metric | SECZ | RIGL |
|---|---|---|
| Price | $13.95 | $47.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 5 |
| Target Price | $13.94 | ★ $63.00 |
| AVG Volume (30 Days) | ★ 3.6M | 156.8K |
| Earning Date | 11-20-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 1867.68 |
| EPS | N/A | ★ 1.32 |
| Revenue | N/A | ★ $294,282,000.00 |
| Revenue This Year | $16.24 | $3.89 |
| Revenue Next Year | $72.48 | $21.95 |
| P/E Ratio | ★ N/A | $37.33 |
| Revenue Growth | N/A | ★ 64.15 |
| 52 Week Low | $5.14 | $24.84 |
| 52 Week High | $17.00 | $52.24 |
Technical Indicators
Market Signals| Indicator | SECZ | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 66.96 | 54.74 |
| Support Level | $5.86 | $43.78 |
| Resistance Level | N/A | $49.50 |
| Average True Range (ATR) | 1.42 | 1.61 |
| MACD | 0.39 | -0.09 |
| Stochastic Oscillator | 75.81 | 65.54 |
Price Performance
Historical ComparisonAbout SECZ Securitize Corp.
Securitize Holdings Inc provides a platform for tokenized real-world assets specializing in tokenizing real-world assets (RWAs) like funds, equities, and fixed income on blockchain networks. The company operates across two primary verticals: i) Tokenization: It consists of on-chain infrastructure and tokenization & distribution, ii) Asset Servicing: It covers post-issuance transfer agent and fund management services. The majority of the company's revenue is derived from the Tokenization vertical.
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.